Beware of Sarepta, CRISPR Therapeutics, and More

Investors should be wary of biotech stocks. Sarepta Therapeutics (SRPT) lost 21.45% yesterday and lost nearly 70% of its value in 2025. The company lost $3.42 a share, despite revenue growing by 80.1% Y/Y to $744.9 million.Sarepta management eroded investor returns when it cut its revenue forecast for this year. Costs from SG&A and research and development will rise, increasing losses for the firm. The drug maker for the treatment of Duchenne muscular dystrophy slashed its revenue forecast by around $500 million. This is due to Elevidys sales.CRISPR Therapeutics (CRSP) lost over 10% in the last week. The firm is pre-profit, reporting revenue of $0.86 million and an EPS loss of $1.58 (non-GAAP). The firm has $1.855 million in cash, down from $1.904 million Q/Q. Short-sellers hold a 24.04% short interest against CRSP stock.Marvell Technologies (MRVL) scared investors when it postponed its investor day. The firm cited macroeconomic uncertainties for its outlook.Among the stocks that investors should consider buying, Disney (DIS) might continue its post-earnings rally today. The firm is forecasting a 16% growth in full-year profit. It also announced a $30 billion theme park investment in an Abu Dhabi resort.Rockwell Automation (ROK) will trend higher after posting a $9.70 EPS target for this fiscal year. In the second quarter, Rockwell reported a revenue decline of 6.1% Y/Y to $2 billion.